Search
CA-170
go.drugbank.com/drugs/DB15772InvestigationalCA-170 is a selective, small molecule inhibitor of PD-L1.
PF-07799933
go.drugbank.com/drugs/DB17489InvestigationalPF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.
Nurulimab
go.drugbank.com/drugs/DB18946InvestigationalNurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in
Secretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalThe main action of secretin is to stimulate the pancreas to secrete pancreatic juice for pH regulation in the small intestines. … The hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 [L1875].
Folic acid
go.drugbank.com/drugs/DB00158ApprovedInvestigationalNutraceuticalVet approvedFolic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purin...
Mixtures: Virt-PN, PR Natal 430LB-P8
go.drugbank.com/drugs/DB18535InvestigationalLB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (_Leuconostoc citreum_).
PD-217014
go.drugbank.com/drugs/DB12493InvestigationalPD-217,014 has been used in trials studying the treatment of Pain and Irritable Bowel Syndrome.
PF-04856884
go.drugbank.com/drugs/DB17550InvestigationalPF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. … [A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).
Ebvaciclib
go.drugbank.com/drugs/DB18967InvestigationalEbvaciclib is under investigation in clinical trial NCT03519178 (A Study of PF-06873600 in People With Cancer).
Mosliciguat
go.drugbank.com/drugs/DB19425InvestigationalMosliciguat is under investigation in clinical trial NCT06635850 (A Phase 2 Study of Mosliciguat in PH-ILD).